Acquisition by Eric Weisblum of 3408 shares of Silo Pharma at 1.94 subject to Rule 16b-3
| SILO Stock | USD 0.90 0.02 2.27% |
About 55% of Silo Pharma's investors are presently thinking to get in. The analysis of current outlook of investing in Silo Pharma suggests that some traders are interested regarding Silo Pharma's prospects. Silo Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Silo Pharma. Many technical investors use Silo Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Silo |
Filed transaction by Silo Pharma Director, Officer: Ceo And President. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Silo Pharma Fundamental Analysis
We analyze Silo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Silo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Silo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Silo Pharma is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Silo Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Silo Pharma otc stock to make a market-neutral strategy. Peer analysis of Silo Pharma could also be used in its relative valuation, which is a method of valuing Silo Pharma by comparing valuation metrics with similar companies.
Peers
Silo Pharma Related Equities
| FBRX | Forte Biosciences | 9.70 | ||||
| RZLT | Rezolute | 1.00 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| URGN | UroGen Pharma | 0.32 | ||||
| LUMO | Lumos Pharma | 0.46 | ||||
| INDP | Indaptus Therapeutics | 0.97 | ||||
| TPST | Tempest Therapeutics | 1.04 | ||||
| IVA | Inventiva | 1.12 | ||||
| SBMFF | Sino Biopharmaceutica | 2.33 | ||||
| BCDA | Biocardia | 2.98 |
Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.